Background: To our knowledge, data are lacking on the role of 18F-FDG PET/CT in the localization and prediction of neuroendocrine tumors, in particular the pheochromocytoma/paraganglioma (PCC/PGL) group. Purpose: To evaluate the role of 18F-FDG PET/CT in localizing and predicting the malignant potential of PCC/PGL. Material and Methods: Twenty-three consecutive patients with a history of PCC/PGL, presenting with symptoms related to catecholamine excess, underwent 18F-FDG PET/CT. Final confirmation of the diagnosis was made using the composite references. PET/CT findings were analyzed on a per-lesion basis and a per-patient basis. Tumor SUVmax was analyzed to predict the dichotomization of patient endpoints for the local disease and metastatic groups. Results: We investigated 23 patients (10 men, 13 women) with a mean age of 46.43 AE 3.70 years. Serum catecholamine levels were elevated in 82.60% of these patients. There were 136 sites (mean SUVmax: 16.39 AE 3.47) of validated disease recurrence. The overall sensitivities for diagnostic CT, FDG PET, and FDG PET/CT were 86.02%, 87.50%, and 98.59%, respectively. Based on the composite references, 39.10% of patients had local disease. There were significant differences in the SUVmax distribution between the local disease and metastatic groups; a significant correlation was noted when a SUVmax cut-off was set at 9.2 (P < 0.05). Conclusion: In recurrent PCC/PGL, diagnostic 18F-FDG PET/CT is a superior tool in the localization of recurrent tumors. Tumor SUVmax is a potentially useful predictor of malignant tumor potential.
Introduction
Pheochromocytomas (PCC) are catecholamineproducing intra-adrenal tumors derived from the sympathetic nervous system. Tumors arising from extra-adrenal chromaffin cells are called sympathetic paragangliomas (sPGL) (1) . sPGLs hypersecrete catecholamines, whereas parasympathetic paragangliomas are most often non-secretory (2) . Nevertheless, unlike most tumors, no molecular or cellular markers can identify PCC/PGL as malignant. Currently, malignant PCC/ PGL is defined only by the presence of metastasis or a recurrent tumor; therefore, information gained by diagnostic and functional imaging in the detection of primary tumors and/or relapsed disease is crucial for further treatment and therapy of neuroendocrine tumors (3, 4) . The risk of malignant transformation is greater for extra-adrenal sPGLs than for PCC or head and neck PGL (5) . Patients with recurrent PCC/PGL should therefore be followed up indefinitely, particularly if they have an inherited form of extra-adrenal tumor. Tumor resection remains the standard treatment for localized disease, as opposed to disseminated metastatic disease (6) . The 5-year survival rate for malignant disease is estimated to be between 34% and 60%, depending on the location of the metastatic disease (4) .
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) provides valuable information on tumor aggressiveness and prognostic stratification in several forms of cancer (7) (8) (9) (10) (11) .
Dedifferentiation causes histological progression to a high grade tumor via dissociation of the organized tumor cell complexes into isolated tumor cells, and this is found together with a loss of most somatostatin receptor (STTR) expression, enabling the cancer cells to invade the host tissue by active locomotion (12) . The cellular reprogramming that underpins this phenomenon is the secondary loss of somatostatin receptor expression, which leads to an increase in glucose utilization and therefore an increase in 18F-FDG uptake on PET as a result of Glut transporter gene upregulation (13) (14) (15) (16) (17) .
To our knowledge, data on the localization and predictive roles of 18F-FDG PET/CT for recurrent PCC/ PGL tumors are lacking. The objective of this study was to evaluate the role of FDG PET/CT in localizing and predicting malignant potential in PCC/PGL.
Material and Methods

Patient accrual
Following approval from the Institutional Ethical Board, we included 23 consecutive patients with a clinical suspicion of PCC/PGL recurrence who were referred to the Centre for Diagnostic Nuclear Imaging, University Putra Malaysia for 18F-FDG PET/CT assessment between April 2010 and April 2012 in our retrospective study ( Table 1) .
The patients had a prior evaluation at the Endocrinology Unit, Hospital Putrajaya, Malaysia, where they presented with signs and symptoms of increased catecholamine levels. Inclusion criteria were patients with a history of previous PCC/PGL, those who presented with sign and symptoms of increased catecholamine levels and those who presented with incidental masses on ultrasound or on sectional imaging in patients who were clinically asymptomatic. Exclusion criteria included pregnant women, breastfeeding mothers, pediatric patients (age <12 years), or patients debilitated by illness.
Patient stratification at the recurrent event
For the purpose of this study, we dichotomized all patients into local disease or the development of metastatic disease as endpoints. Tumors in the local control group were those lesions that recurred metachronously along the Zuckerkandl body and vestigial chromaffin ganglion located at the root of the upper mesenteric artery and the sympathetic plexus of the urinary bladder, kidneys and heart, and sympathetic ganglia in the mediastinum. Tumors in the metastatic group were those with distant metastasis as evidenced by the presence of metastases, predominantly in bone, lungs, liver, and lymph nodes (where the chromaffin cells are absent).
All subjects were required to fast for at least 6 h prior to PET/CT (18F-FDG PET/CT); only oral hydration with glucose-free water was allowed. After verification of a normal blood glucose level in the peripheral blood (<7.00 mmol/L), patients received an intravenous injection of 370 MBq (10 mCi) of fluorodeoxyglucose (FDG) and then rested for approximately 30-45 min before undergoing PET/CT imaging. Image acquisition was performed with an integrated PET/CT device (Siemens Biograph-64, Erlangen, Germany) consisting of a 3D-PET camera (lutetium oxyorthosilicate) and a 64-MDCT scanner. Patients were allowed to perform normal shallow respiration during acquisition of the PET-CT. The contrasted CT scan was performed first at 120 kv, 150 mAs transmission with a pitch of 0.8 (5.0 mm slice thickness) from the base of the skull to the proximal thighs for the purpose of anatomical localization and attenuation correction to rescale FDG PET image attenuation without delay at the second time point. Iopamidol-300 was used at the injection rate of 5 mL/s. PET emission was performed contemporaneously with acquisition for 3 min per bed position. CT data were resized from a 512 Â 512 matrix to a 128 Â 128 matrix to match the PET data to allow image fusion, and CT transmission maps were generated. PET image datasets were reconstructed iteratively with the orderedsubsets expectation maximization (OSEM) algorithm with segmented measured attenuation correction (two iterations, 28 subsets) of the CT data. Co-registered images were displayed on the Siemens-Leonardo workstation.
Image interpretation
Two nuclear medicine physicians/radiologists with >10 years of clinical experience who read the results were not blinded to the diagnosis but were blinded to the clinical data and the biochemical findings and the patient's management strategy. For the purpose of interpretation, results were grouped according to the qualitative assessment on a per-lesion and per-patient basis on the combined FDG PET/CT. On the perlesion basis, positive lesions were detected when there was evidence of enhancement on CT that was higher than the muscle density. In contrast, a lesion with higher inherent metabolic activity than the mediastinal blood pool on FDG PET determined a positive finding (18) . On the per-patient basis, a positive lesion was detected when there was evidence of abnormal FDGavid lesions on the FDG PET multiple image projection (MIP).
Quantitative PET/CT image analysis
The SUVmax was derived from the mean of all FDGpositive lesions. CT scans were also analyzed for lesion location, size, and the pattern of regional tumor infiltration. Lymph nodes with a short-axis diameter >10 mm were defined as abnormal (19) .
Histopathology
The histological diagnoses were made when tissue samples were obtained from either biopsy or resected lesions during surgery. The diagnosis of PCC/PGL lesions was made by histopathological evaluation of 4 mm thick hematoxylin and eosin stained sections prepared from representative, paraffin-embedded tissue sections of surgical specimens after fixation in 10% buffered formalin. Confirmatory immunohistochemical staining was performed using standard procedures in a DAKO autostainer using antisera against S-100 (1 : 500; DAKO), chromogranin (1 : 1000; DAKO), and synaptophysin (1 : 100; DAKO). PCC/PGL lesions exhibit positivity for chromogranin and synaptophysin. In addition, S-100 immunostaining highlights the presence of sustentacular cells that typically surround nests of tumor cells. The absence of positivity for epithelial membrane antigen helps distinguish PCC from other tumors, i.e. renal cell carcinoma. Features of malignant PCC/PGL include confluence of tumor necrosis, presence of vascular invasion and/or extensive local invasion, and >50% of intracytoplasmic hyaline globule. Benign features include well-encapsulated tumor, no necrosis, and <40% intra-cytoplasmic globule.
Composite reference
Histological data were used to confirm recurrence with the presence of at least one of the following three criteria: elevated serum catecholamine level, clinical follow-up (catecholamine-related symptoms), or positive new lesions on a standalone CT imaging technique used to validate the presence of PCC/PGL lesions.
Statistical analysis
Mean, SD, range, and frequencies were used to describe the data. Differences in the mean-rank of the variables were analyzed by Mann-Whitney test. Tests of the accuracy of diagnostic CT, FDG PET, and the combined data were calculated using the composite reference as the standard. The area under the curve given by the receiver-operating curve (ROC) is a measure of SUVmax discrimination, that is, the ability of the test to correctly classify those with LC and the metastasis.
The range given at the curve point of 0.786 AE 0.098 had drawn pairs of sensitivity and specificity of 61.5% and 77.7% for which the discrimination of the two classified groups is true when the value of 9.2 is chosen (P < 0.05). A separate analysis was performed to optimize the cut-off value of the tumor size of 2.0 cm. The clinical risk factors of sex, serum catecholamine levels, tumor type, tumor SUVmax, maximum tumor size (cm) were evaluated as predictors of disease endpoints using the Chi-square and Fisher's Exact tests. A two-sided P value of <0.05 was considered significant.
Results
Patient characteristics
Twenty-three patients (10 men, 13 women), with a mean age of 46.43 AE 3.70 years, were investigated in this study. All but one patient had survived at the close-out date, with a mean follow-up duration of 19.35 AE 3.34 months. Twenty-three patients presented with recurrent disease, and three of these patients presented with recurrent lesions in the contralateral adrenal glands. Nine patients (39.1%) had local control when the recurrent event occurred on the combined FDG PET/CT. Serum catecholamine levels were elevated in 19/23 patients (82.6%) ( Table 2) .
FDG PET/CT for tumor localization
Based on the composite reference, there were 136 sites (mean SUVmax: 16.39 AE 3.47 g/mL) of validated disease recurrence. The mean size of the PCC/PGL lesions was 0.87 AE 0.61 cm. Tumor lesions were present predominantly in the abdomen and pelvis (52.9%) ( Table 2 ). The overall diagnostic sensitivities for CT, FDG PET, and FDG PET/CT were 117/136 (86.0%), 119/136 (87.5%), and 134/136 (98.5%), respectively (Table 3) . On a per-lesion basis, there were six falsenegative FDG PET lesions that were identified as enhanced lesions on CT, of which four lesions were obscured by FDG-avid brown fat uptake (Fig. 1) and two lesions were necrotic (Fig. 2) . On the other hand, there were imperceptible CT lesions noted in one patient and small volume lesions in seven patients, which were below the CT size criteria but positive on the FDG PET assessments (Fig. 3) . In two patients, both CT and FDG PET were negative; follow-up assessment of these patients with persistently raised catecholamine levels revealed progressive lesions mistaken for partial voluming of the normal bowel loop (Fig. 4) . On FDG PET-CT, most of the equivocal lesions on either CT or FDG PET were further detected, rendering an improved diagnostic accuracy of 98.5% (134/136). On a per patient basis, 18 patients were positive by FDG PET, whereas five patients were negative. All the five FDG-negative patients were positive on CT alone. The mean SUVmax between the two groups (FDG-positive vs. FDG-negative) was significantly different (P < 0.002; Fisher's Exact test) ( Table 4) .
Tumor standardized uptake value (SUVmax) and size
There was a significant difference in the mean SUVmax between the groups with local control (7.78) and metastatic disease (14.08) (P < 0.05 Mann-Whitney tests) (Fig. 5 ). There were significantly more patients with metastatic disease (8) who had a SUVmax >9.2, compared to the local disease group (P < 0.05; Fisher's Exact test) ( Table 5) . Of those with a SUVmax <9.2, there were nine patients with metastatic disease and six patients with local disease (P < 0.05; Fischer's Exact test) (Table 5 ). There was also a significant difference in the number of patients whose tumor size was >2.0 cm in the metastatic group (five) than in the local disease group (none) (P < 0.05; Fischer's Exact test) ( Table 5 ). There was no difference between the numbers of patients who had either increased or normal serum catecholamine levels in both of the endpoint groups. By the validated final diagnosis, 12 patients had PCC and 11 patients had PGL lesions without any significant difference in the mean SUVmax (P > 0.05; Mann-Whitney tests) ( Table 4) .
Patient management
Tumor resection is the mainstay of treatment in 18 patients, whereas five patients were put on conservative management (Table 1) . No significant difference in the mean SUVmax was found between the two groups (P > 0.05; Mann-Whitney tests) ( Table 4) . One patient (P9) with local disease had declined treatment (Table 1) . At the close-out date, one patient (P12) with FDG-negative metastatic disease had died (Table 1) . This patient had declined radiopeptide therapy; a subsequent 68 (Ga)-DOTATOC study at another center (image not available) revealed DOTATOC avidity for all of the metastatic lesions.
Discussion
It should be noted that the use of non-FDG PET tracers, such as 68 (Ga)-DOTATOC, 18 (F)-DOPA or 18 (F)-dopamine, could also potentially reveal the characteristics of aggressive PCC/PGL, but there are limited published data on the role of these imaging modalities for localizing or predicting the recurrence of PCC/PGL (20, 21) . There is an emerging role of 18F-FDG PET/ CT in localizing and predicting the malignant potential of PCC/PGL recurrences but for which current data are lacking, to the best of our knowledge. On a per-lesion basis, we found that CT had a sensitivity of 86.0%, which was lower than the sensitivity of 18F-FDG PET/CT (98.5%). This is in accordance with another study series that demonstrated a high sensitivity of 18F-FDG PET/CT in evaluating patients with other tumors, including metastatic paraganglioma (22, 23) .
On a per-patient basis, the majority of our patients were FDG-positive (18/23; 78.2%). With the FDG PET and CT combination, the sensitivity of detecting recurrent tumor lesions was improved (100%), making it a reliable assessment tool in distinguishing lesions with malignant potential and worse disease prognosis (16) . The diverse biological features of PCC/PGL make this group of tumors different from other neuroendocrine tumors in which aggressive disease is most commonly associated with mutations in the SDHB gene; this mutation occurs in an estimated 40% of cases when primary tumors are located in the abdomen (24) . This cohort also included a familial pair of patients with FDG-avid metastases who were highly suspicious for the associated genetic mutation (24) . However, genetic profiling was not performed for further validation.
In imaging chromaffin-derived tumors, our results suggest that PET/CT using FDG is useful in localizing potentially malignant lesions when they have a higher risk of recurrence. The use of the contrasted CT technique in our protocol, in combination with FDG PET, helped to unequivocally distinguish FDG-negative lesions, as illustrated in six patients (Figs. 1 and 2) .
The use of a glycolytic indicator, such as FDG in PET/CT, is a promising method to predict the malignant potential of a tumor. SUVmax has been used as a surrogate marker in various tumors types for which high SUV values are associated with more aggressive disease and serve as a reliable indicator for disease prognostication (25) (26) (27) (28) (29) (30) (31) (32) . The higher value of SUVmax reflects the degree of altered metabolism by the tumor, as some benign tumors would not be differentiated from malignant (13) .
We found a promising role for the semiquantitative value of SUVmax in predicting the malignant potential of a tumor when a SUVmax cut-off value of 9.2 was used. The advantage of this dichotomization between local and metastatic disease is that no baseline PET study is required, and the results are not subjected to methodological variations. In this cohort of patients, we found that more patients with a SUVmax greater than 9.2 had metastatic lesions when compared to those with local disease only. Our result suggests that patients with metastatic disease and high malignant potential (recurrence tendency) have altered tumor glycolysis, as quantified by SUVmax. This evidence is substantiated by another study series that demonstrated the correlation between the degree of deranged glycolysis and tumor aggressiveness (33, 34) . High SUVmax values in recurrent tumor lesions denote the upregulation of tumor glycolysis when the tumor undergoes dedifferentiation, which construes the so called ''flipflop'' described in the shift of the imaging modality of choice, from the more specific 18F-FDA PET to the less specific 18F-FDG PET (15, 19) .
In the setting of deciding whether a patient could be considered for a surgical or non-surgical approach, the SUVmax value may also be a potential predictive marker if a prospective method were applied to this study. The insignificance of SUVmax differences between the groups may be attributable to the fact that some of the symptomatically treated patients with metastatic disease could have benefited from chemotherapy or targeted therapies, for which treatment is unavailable in our setting.
In addition to SUVmax, tumor size is also an important factor in predicting tumor aggressiveness. In our study, the cut-off tumor diameter of 2.0 cm was associated with more patients who had metastatic lesions. This observation is in agreement with the findings by Timmers et al., who found that a tumor size of >5 cm was a strong predictor of invasive or metastatic disease (21) .
Although these results are promising and support the use of a SUVmax cut-off value as a predictor of tumor malignant potential, larger studies are needed to confirm the value of this parameter in PCC/PGL recurrence, not only as a predictive factor but also for prognostic stratification. A potential application could be that, in patients with local disease on FDG PET/CT but with a high SUV in the local tumor, the likelihood of developing metastatic recurrence (post-resection) could be greater. This notion is, however, not demonstrated in our study as the number of subjects was too small for an appropriate analysis. In addition, the MRI data were not available in this study series for which sensitivity as a PCC/PGL localizer is better than the CT (35) . The use of MRI-PET combination in the future may potentially serve as a powerful tool in detecting and predicting PCC/PGL malignant potential. Other limitations include the composite reference on the perlesion analysis for which the use of non-histological reference standards may pose a statistical bias, especially when an evidence of tumor was only made by the incremental value of the FDG PET/CT results. Nevertheless, our results suggest that FDG PET/CT assessment prior to definitive treatment is likely to be beneficial in terms of both tumor dichotomization and treatment planning, as well as providing useful prognostic information in recurrent PCC/PGL. In this regard, SUVmax as a glycolytic indicator may become a new benchmark of disease dedifferentiation.
In conclusion, 18F-FDG PET/CT is a highly accurate tool for the localization of recurrent PCC/PGL. SUVmax may potentially be a valuable predictor of the presence of metastatic disease in PCC/PGL tumors that indicate tumor aggressiveness, and it allows for better stratification of treatment groups between those with local disease control and the distant metastatic tendency of PCC/PGL recurrence.
